Bioelectronics

Gense Technologies

Portable self-help medical imaging device for home-based diagnostic screening and chronic disease monitoring in lung, liver, kidney and more

Gense offers an affordable and portable self-help medical imaging device for in-depth health monitoring and diagnostic screening at home and clinics. The device targets some of the costliest diseases’ early detection and monitoring, specifically in preventive care and chronic disease management.

Developed as a home-based medical imaging modality to assist telemedicine, the imaging scan can be self-administrable by users without substantive operative training. It is also powered by cloud-based machine learning algorithms to monitor liver, lungs and more.

Specifically, users can connect the palm-sized medical imaging device to their mobile phones, follow simple in-app instructions for 5-minute radiation-free scans, and share results with healthcare providers of their choosing via a secured cloud platform.

The award-winning startup is built by a team of 15 PhDs and researchers from Stanford, Cambridge, and Hong Kong. The team is also coordinating over 8 partnerships with professors on clinical trials, machine learning, biomedical imaging, and mathematical modelling.

The startup has conducted successful pilot studies in liver and lung monitoring, with ongoing trials including Non-Alcoholic Fatty Liver Disease, Chronic Obstructive Pulmonary Disease, lung cancer, and tendon disorders. They are also running a Hong Kong government sponsored trial in COVID recovery remote monitoring for discharged patients.

Gense has raised over USD 2.5mil from grants and investment to date, and has developed capacity to mass manufacture with medical device certification. The next round of clinical trial will be completed within 6 months at the commercial launch of the product.

The startup has also been approached by healthcare distributors from over 20 markets globally to set up local deployment pipeline, including private hospital network, clinic chains, health insurers, and multinational conglomerates.